The former vice president of R&D for drug-coated balloon maker Lutonix, Christopher Barry, yesterday pleaded guilty to a single count of trade secret theft in federal court in Minneapolis. Barry, who left Lutonix in 2015 to become CEO of Urotronic, admitted to downloading 6 files in April 2015 containing trade secrets about the development of […]
C.R. Bard
BD launches $1B exchange offer for Bard notes, looks to raise $4.5B in offering
Becton Dickinson (NYSE:BDX) said last week it launched an exchange for up to up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes as well as its own financing round that could bring in as much as $4.5 billion. The company said it will offer exchanges for approximately $500 million for 4.4% Bard note due 2021, $500 million for […]
Bard shares soar on solid Q1, BD merger
C.R. Bard (NYSE:BCR) today released Q1 earnings which significantly topped expectations, as well as announcing its $24 billion acquisition by Becton Dickinson & Co. (NYSE:BDX), sending shares through the roof, up more than 20% in early-day trading. The Murray Hill, N.J.-based company posted profits of $178.1 million, or $2.37 per share, on sales of $938.8 million […]
Becton Dickinson to acquire Bard in $24B deal
Becton Dickinson (NYSE:BDX) has inked an agreement with C. R. Bard (NYSE:BCR) to acquire the medtech company for $317.00 per Bard common share in cash and stock, valuing the deal at $24 billion. In announcing the deal yesterday, Franklin Lakes, N.J.-based BD said it plans to create a new segment within the company, BD Interventional, to […]
Trumpcare’s prospects dim, but not too dim to hit stent graft makers
The push on Capitol Hill to revive Trumpcare stalled yesterday, but not before the chatter out of Washington instigated a slide for stent graft makers’ stocks. The Affordable Care Act covers a 1-time screening for abdominal aortic aneurysms in men who smoke or smoked in the past, listing the test as an “essential health benefit.” The […]
Bard logs win in long-running stent graft patent spat with Gore
A Delaware federal jury awarded a win to C.R. Bard (NYSE:BCR) in an ongoing spat with W.L. Gore & Associates over ultra thin stent graft patents. The 8-man jury ruled that Bard’s patent does not infringe on Gore’s patent, and that Gore’s patent is invalid, according to court documents released yesterday.. The ruling is the most recent […]
Gore must cough up fees to cover pursuit of sanctions in stent graft spat with Bard
A federal judge in Delaware yesterday ordered W.L. Gore & Assoc. to cough up some of the legal fees C.R. Bard (NYSE:BCR) incurred in defending itself against Gore’s bid for sanctions against Bard’s lawyers in their long-running war over stent graft patents. Gore alleged that the Bard legal time conspired to sit on an expert witness report […]
Donald Trump: What medtech’s top executives are saying
For the most part, the medical device industry’s top executives have sounded positive about the new Trump administration and Republican Congress during recent earnings calls with analysts. Some such as Johnson & Johnson CEO Alex Gorsky have even offered advice. And while there are many open questions, top executives insist potential repeal and replace of […]
FDA: Bard recall of Halo One guiding sheath is Class I
The FDA today announced a Class 1 recall of C.R. Bard’s (NYSE:BCR) the Halo One thin-walled guiding sheaths over issues associated with sheath separation, kinking and tip damage during use. The Murray Hill, N.J.-based company’s Halo One sheath is designed to introduce and guide the placement of interventional or diagnostic devices into veins and arteries […]
C.R. Bard’s Q4 sales, earnings beat estimates
C.R. Bard (NYSE:BCR) beat the consensus forecast with its 4th-quarter results yesterday, with both sales and earnings growing at a double-digit clip. The Murray Hill, N.J.-based healthcare giant posted profits of $159.6 million, or $2.11 per share, on sales of $967.1 million for the 3 months ended Dec. 31, 2016. That amounts to profit growth […]
Medtronic touts low CD-TLR rates, strong durability in 3-year In.Pact Admiral DCB study | VIVA 2016 Roundup
Medtronic (NYSE:MDT) this week released data from 2 clinical studies evaluating its In.Pact Admiral drug-coated balloon for treating claudication and restenosis, touting sustained durability at 3-years. Results were presented at the Vascular Interventional Advances 2016 conference in Las Vegas this week. Those of you who want strength without size, lean muscles, or if you’re cutting, http://topsteroidsforsale.com is relatively safe […]